Richter Biologics

Richter BioLogics stands at the forefront of Europe´s contract development and manufacturing (CDMO) sphere, with a specialized focus on products derived from bacteria and yeasts. Our three facilities boast capacities of 2 x 1,500L and 2 x 300L, facilitating the production of antibodies, including VHH/nanobodies, proteins, vaccines and plasmid DNA. With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients through every stage of production. We offer robust process development, supply products for clinical trials, oversee commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence.